服务服务

Comprehensive genetic disease diagnosis and birth defect prevention across the full care continuum, from premarital and preconception screening through newborn genomic screening.

Genetic diagnostic testing is regulated differently in every jurisdiction. Panels are provided as laboratory services; local validation and accreditation are supported, and the regulatory dossier remains with the local institution.

Over 1,000 tumour-related genetic tests evaluating therapy targets per clinical guidelines, spanning targeted therapy, immunotherapy and chemotherapy selection.

Provided as a laboratory service. Results inform clinical decision-making by the treating physician; they are not a treatment recommendation and do not replace clinical judgement.

Blood-based gene methylation analysis for early cancer detection, applicable to lung, thyroid, liver, colorectal, gastric and oesophageal cancer.

Provided as a laboratory service for early detection. Reported sensitivity advantages over traditional tumour markers derive from the partner laboratory’s internal studies; independent validation data should be requested during feasibility.

Detection of vascular endothelial growth factor abnormalities across the cancer care continuum: early detection, treatment efficacy evaluation and post-treatment recurrence monitoring.

Provided as a laboratory service. Intended to support, not replace, established imaging and histopathological assessment.

Metagenomic and targeted next-generation sequencing for infectious disease, covering over 30,000 microorganisms and more than 2,000 antimicrobial resistance genes.

Clinical use of metagenomic sequencing is regulated as a diagnostic and varies by jurisdiction. Surveillance and research applications typically sit under a different framework.

Plasma multi-biomarker assessment including the Aβ1-42/Aβ1-40 ratio and p-tau217, identifying individuals who may require confirmatory PET or CSF evaluation.

A screening test, not a diagnosis. Abnormal plasma results trigger confirmatory PET or CSF analysis combined with medical history, family history and neuropsychiatric scale assessment.

Precise assessment of over 75 immune cell subpopulations across T cells, NK cells, gamma delta T cells and B cells for immune function evaluation and disease risk assessment.

Provided as a laboratory service for immune function assessment. Risk indications are probabilistic and are not a diagnosis of any specific condition.

Comprehensive analysis of gut microbial structure at phylum and genus level, covering immunity, nutrient metabolism, short-chain fatty acid synthesis, toxin degradation and allergy risk.

Provided as a laboratory service. Microbiome-derived risk assessments are associative and should be interpreted alongside clinical assessment.

FMT products in capsule and suspension form, recommended by clinical guidelines for recurrent or refractory Clostridioides difficile infection.

Guideline-recommended for recurrent or refractory C. difficile infection only. Application to IBS, IBD, chronic constipation, neuropsychiatric conditions, metabolic disorders and tumour immunotherapy is an area of active investigation and is not established care.

Thirteen bacterial strains, some patent-pending, combined with prebiotics for functional products targeting immune regulation, pathogen inhibition and nutrient absorption.

Product development capability. Strains are patent-pending; classification as food supplement or therapeutic differs by jurisdiction and determines the applicable regulatory pathway.

Patient-derived organ models across seven cancer types with screening against more than a hundred targeted drugs.

Supported for research collaboration and translational study. Results are not offered as a basis for treatment decisions outside a clinical trial.

Stem cell portfolio and cellular derivative production, including stem cell and immune cell exosomes for cell-free therapeutic and diagnostic applications.

Stem cell and exosome products are investigational outside defined trial settings in most jurisdictions. VectorGene does not present investigational products as standard care.

Chronic food sensitivity, hair nutrient and toxic element screening, allergen-specific antibody testing and NAD+ optimisation.

Wellness and preventive assessments. IgG-based food sensitivity testing is not accepted by all clinical bodies as a diagnostic for food allergy; results are for dietary guidance and should not replace allergy diagnosis by a clinician.

Polygenic and monogenic risk assessment across cancer, endocrine, autoimmune, cardiovascular and age-related disease, with integrated genetic counselling.

Risk assessment is probabilistic and is not a diagnosis. Results should be delivered with genetic counselling; several assessments in this group have limited clinical utility evidence and should be positioned accordingly.